{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:28Z","timestamp":1790188168558,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.intimp.2023.111086","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:35:53Z","timestamp":1698150953000},"page":"111086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis"],"prefix":"10.1016","volume":"125","author":[{"given":"Xiaojuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-3606","authenticated-orcid":false,"given":"Jianzhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2019.11.009","article-title":"Origins of rheumatoid arthritis","volume":"87","author":"Boissier","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2023.111086_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2023.111086_b0015","doi-asserted-by":"crossref","first-page":"ITC1-ITC16","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2023.111086_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106367","article-title":"Thermosensitive smart hydrogel of PEITC ameliorates the therapeutic efficacy in rheumatoid arthritis","volume":"181","author":"Haloi","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.111086_b0025","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955\u20132007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/acr.20041","article-title":"Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001\u20132005","volume":"62","author":"Sacks","year":"2010","journal-title":"Arthritis Care Res (hoboken)"},{"key":"10.1016\/j.intimp.2023.111086_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/39.suppl_2.3","article-title":"Epidemiology of rheumatic diseases","volume":"39","author":"Sangha","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"10086","key":"10.1016\/j.intimp.2023.111086_b0040","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.intimp.2023.111086_b0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/psb.1945","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"32","author":"Weddell","year":"2021","journal-title":"Prescriber"},{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.intimp.2023.111086_b0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-020-00921-8","article-title":"Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment","volume":"22","author":"Drosos","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.111086_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.intimp.2023.111086_b0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"21","key":"10.1016\/j.intimp.2023.111086_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113394","article-title":"CS12192, a Novel JAK3\/JAK1\/TBK1 inhibitor, synergistically enhances the anti-inflammation effect of methotrexate in a rat model of rheumatoid arthritis","volume":"23","author":"Fang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2023.111086_b0080","doi-asserted-by":"crossref","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are Janus kinase inhibitors superior over classic biologic agents in RA patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"12","key":"10.1016\/j.intimp.2023.111086_b0085","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/25785826.2020.1770948","article-title":"JAK inhibitors for the treatment of rheumatoid arthritis","volume":"43","author":"Morinobu","year":"2020","journal-title":"Immunol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.111086_b0095","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.111086_b0100","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2023.111086_b0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2023.111086_b0110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2023.111086_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cyto.2016.10.012","article-title":"The promise of Janus kinase inhibitors in the treatment of hematological malignancies","volume":"98","author":"Senkevitch","year":"2017","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.intimp.2023.111086_b0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.111086_b0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK Inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr. J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111086_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrrheum.2013.7","article-title":"Back to the future: oral targeted therapy for RA and other autoimmune diseases","volume":"9","author":"O'Shea","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"24","key":"10.1016\/j.intimp.2023.111086_b0135","doi-asserted-by":"crossref","first-page":"16716","DOI":"10.1021\/acs.jmedchem.2c01550","article-title":"Identification of TUL01101: A novel potent and selective JAK1 inhibitor for the treatment of rheumatoid arthritis","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2023.111086_b0140","first-page":"0318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111086_b0145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2023.111086_b0150","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J. Exp. Med."},{"issue":"22","key":"10.1016\/j.intimp.2023.111086_b0155","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2023.111086_b0160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V88.3.817.817","article-title":"Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene","volume":"88","author":"Villa","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2023.111086_b0165","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.intimp.2023.111086_b0170","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","article-title":"Discovery of VX-509 (Decernotinib): A potent and selective janus kinase 3 inhibitor for the treatment of autoimmune diseases","volume":"58","author":"Farmer","year":"2015","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2023.111086_b0175","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.intimp.2023.111086_b0180","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2023.111086_b0185","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.intimp.2023.111086_b0190","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1021\/jm200326p","volume":"54","author":"William","year":"2011","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.intimp.2023.111086_b0195","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2023.111086_b0200","first-page":"ii3-ii10","article-title":"JAK1: Number one in the family; number one in inflammation?","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.111086_b0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"JAKS AND STATS: Biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.111086_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"issue":"28","key":"10.1016\/j.intimp.2023.111086_b0215","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2023.111086_b0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology"},{"issue":"10139","key":"10.1016\/j.intimp.2023.111086_b0225","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.intimp.2023.111086_b0230","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2023.111086_b0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"7","key":"10.1016\/j.intimp.2023.111086_b0240","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.111086_b0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/08923973.2018.1434793","article-title":"Experimental animal models for rheumatoid arthritis","volume":"40","author":"Choudhary","year":"2018","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111086_b0250","doi-asserted-by":"crossref","first-page":"e5646","DOI":"10.1590\/1414-431x20165646","article-title":"Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies","volume":"49","author":"Andrade","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.intimp.2023.111086_b0255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111086_b0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jcsm.12280","article-title":"Collagen-induced arthritis as an animal model of rheumatoid cachexia","volume":"9","author":"Alabarse","year":"2018","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.intimp.2023.111086_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105914","article-title":"Therapeutic treatment of a novel selective JAK3\/JAK1\/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis","volume":"77","author":"Shan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2023.111086_b0270","unstructured":"Administration, FDA. Upadacitinib REVIEW (NON-CLINICAL REVIEWS). 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000PharmR.pdf."},{"issue":"5","key":"10.1016\/j.intimp.2023.111086_b0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/berh.2001.0187","article-title":"The balance of Th1\/Th2 cytokines in rheumatoid arthritis","volume":"15","author":"Schulze-Koops","year":"2001","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2023.111086_b0280","unstructured":"Administration, FDA. tofacitinib REVIEW (Pharmacology Reviews). 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000PharmR.pdf."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923014121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923014121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:07:41Z","timestamp":1761588461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923014121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":56,"alternative-id":["S1567576923014121"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111086","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111086"}}